8-K: United Health Products Provides Update on FDA Premarket Approval Application for HemoStyp Gauze

United Health Products announced an update on its FDA Premarket Approval application for its HemoStyp gauze, including the need for additional clinical data.

Summary

• United Health Products (UHP) provided an update on its FDA Premarket Approval (PMA) application for its HemoStyp gauze, now called CelluSTAT.
• Following a Submission Issue Request (SIR) in August 2024, UHP held a videoconference with the FDA on October 29, 2024, to discuss deficiencies in the PMA application.
• The FDA requested additional data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, despite positive results from a clinical trial involving 232 patients.
• UHP plans to conduct a multi-site study with a limited number of human subjects undergoing surgical procedures within the organ space.
• The company anticipates this process will take approximately 6-7 months to complete, during which time additional biocompatibility and sterility testing will also be conducted.
• The FDA's 180-day application review period is paused until UHP submits responses to all deficiencies, with approximately 90 days already elapsed.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has made progress and is optimistic, the need for additional studies and the resulting delay are negative factors. The sentiment is neutral to slightly negative due to the delay.

Positives

• The clinical trial demonstrated both non-inferiority and superiority for time to hemostasis using CelluSTAT.
• The clinical trial results showed no evidence of heterogeneity across various factors.
• No adverse events in the clinical trial were attributed to the hemostatic gauze.
• The FDA has confirmed that concerns regarding vascular graft procedures have been addressed.
• The company has clarity on the remaining tasks to resolve the deficiencies in the PMA application.
• The company is optimistic about the outcome of the application process.

Negatives

• The FDA requires additional data for organ space applications despite positive clinical trial results.
• The additional study will take an estimated 6-7 months to complete, delaying the PMA application process.
• The FDA's 180-day review period is paused until all deficiencies are addressed.

Risks

• The additional study may not yield the desired results, potentially further delaying or jeopardizing the PMA application.
• The 6-7 month timeline for the additional study could be extended due to unforeseen circumstances.
• There is no guarantee that the PMA application will be approved, even with the additional data.
• The company will need to allocate resources to complete the additional study, which may impact other operations.

Future Outlook

The company anticipates completing the additional surgical procedures and testing within 6-7 months and is optimistic about the outcome of the PMA application process.

Management Comments

• Brian Thom, CEO, stated that the company is pleased to confirm the path to resolving the deficiencies in the PMA application.
• Brian Thom also expressed disappointment that the strong results of the pivotal study were not sufficient to address the FDA's concerns regarding organ space applications.
• Brian Thom noted that much progress has been made since submitting the PMA application in March.
• Brian Thom stated that the company has never been more optimistic regarding the outcome of the application process.

Industry Context

The announcement highlights the rigorous regulatory process for medical devices, particularly those involving surgical procedures. The FDA's request for additional data, despite positive initial results, underscores the importance of comprehensive safety and efficacy data, especially in sensitive areas like organ space applications. This is consistent with the industry's focus on patient safety and regulatory compliance.

Comparison to Industry Standards

• The FDA's request for additional data in organ space applications is not uncommon for hemostatic devices, as these areas present unique challenges due to organ movement and difficulty in observing postoperative rebleeding.
• Companies like Baxter (with products like Floseal) and Ethicon (with products like Surgicel) have also faced rigorous scrutiny during the approval process for their hemostatic agents, often requiring multiple clinical trials and post-market surveillance.
• The 6-7 month timeline for the additional study is within the typical range for such studies, although it does represent a delay in the overall approval process.
• The FDA's Bioresearch Monitoring program (BIMO) site inspections are a standard part of the PMA process, ensuring data integrity and adherence to study protocols.

Stakeholder Impact

• Shareholders may experience a delay in the potential commercialization of CelluSTAT.
• Employees will be involved in the additional study and testing.
• Customers (surgeons and hospitals) will have to wait longer for the product to become available.
• Suppliers may see a delay in orders related to the product.

Next Steps

• Submit an Investigational Device Exemption (IDE) for FDA approval.
• Recruit a contract research organization to assist in data collection and monitoring.
• Evaluate and select 3-5 suitable sites for the surgical procedures.
• Enroll patients in the multi-site study.
• Conduct patient follow-up.
• Process and analyze the data from the additional study.
• Complete additional biocompatibility and sterility testing.
• Submit responses to all deficiencies to the FDA.

Key Dates

Keywords

FDA, Premarket Approval, PMA, HemoStyp, CelluSTAT, hemostatic gauze, clinical trial, biocompatibility, sterility, organ space, surgical procedures, Investigational Device Exemption, IDE